You are here: Industry Insights > NMPA

News List

How to register a drug into the market in China? ChatGPT/PharmaSources
November 08, 2023
Registering a drug for market approval in China involves a comprehensive and multi-step process that requires adherence to the country's regulatory requirements.
Drug Marketing in China and Worldwide (September)(2023) PharmaSources
October 01, 2023
For the importance of disease monoclonal antibodies, the drug ingredient is still being tested.
Drug Marketing in China and Worldwide (July) Caicai/PharmaSources
August 11, 2023
On July 6th, Eisai's lecanemab (Leqembi) was fully approved by the FDA for the treatment of Alzheimer's disease
Drug Marketing in China and Worldwide (August)(2023) PharmaSources
September 01, 2023
The official website shows that the drugs developed by major companies have been declared for marketing.
Drug Marketing in China and Worldwide (June) Caicai/PharmaSources
July 12, 2023
Drug Marketing in China and Worldwide (June)
NMPA's Progress in Joining PIC/S zhulikou431/PharmaSources
July 12, 2023
This article will introduce China NMPA's progress in joining PIC/S and the latest change in GMP guideline of PIC/S respectively.
Drug Marketing in China and Worldwide (May) Caicai/PharmaSources
July 12, 2023
Drug Marketing in China and Worldwide (May)
Regulation and response to drug shortages in China PharmaSources/zhulikou431
June 12, 2023
China's regulation of and response to drug shortages.
Drug Marketing in China and Worldwide (April) PharmaSources
May 12, 2023
Summary of Drug Marketing at Home and Abroad (April)
The drug regulatory landscape in China: Progress and Reform Deborah Seah
April 20, 2023
Since 2015 when drug approval policies and process have begun its reform, China has seen improvements in both the speed and predictability of drug approvals over the past few years.